

# Francois Rozet

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/345614/francois-rozet-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

52  
papers

685  
citations

15  
h-index

24  
g-index

58  
ext. papers

984  
ext. citations

3.3  
avg, IF

3.94  
L-index

#	Paper	IF	Citations
52	Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 967-976	12.9	94
51	The role of chemotherapy in the treatment of urothelial cell carcinoma of the upper urinary tract (UUT-UCC). <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2013</b> , 31, 407-13	2.8	58
50	Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy. <i>European Urology</i> , <b>2019</b> , 75, 231-239	10.2	53
49	A proportion of hereditary upper urinary tract urothelial carcinomas are misclassified as sporadic according to a multi-institutional database analysis: proposal of patient-specific risk identification tool. <i>BJU International</i> , <b>2012</b> , 110, E583-9	5.6	48
48	The evolution of bladder cancer genomics: What have we learned and how can we use it?. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2018</b> , 36, 313-320	2.8	47
47	Upper urinary tract instillations in the treatment of urothelial carcinomas: a review of technical constraints and outcomes. <i>World Journal of Urology</i> , <b>2013</b> , 31, 45-52	4	30
46	Prospective assessment and histological analysis of adherent perinephric fat in partial nephrectomies. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2017</b> , 35, 39.e9-39.e17	2.8	30
45	Adrenal tumours are more predominant in females regardless of their histological subtype: a review. <i>World Journal of Urology</i> , <b>2013</b> , 31, 1037-43	4	26
44	Mismatch repair (MMR) detection in urothelial carcinoma (UC) and correlation with immune checkpoint blockade (ICB) response.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4511-4511	2.2	19
43	Psychosocial impact of penile carcinoma. <i>Translational Andrology and Urology</i> , <b>2017</b> , 6, 874-878	2.3	18
42	Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma. <i>Human Pathology</i> , <b>2018</b> , 77, 63-69	3.7	18
41	Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial Carcinoma. <i>European Urology Focus</i> , <b>2019</b> , 5, 201-204	5.1	18
40	Prospective implementation of a nonopioid protocol for patients undergoing robot-assisted radical cystectomy with extracorporeal urinary diversion. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2019</b> , 37, 300.e17-300.e23	2.8	17
39	Modeling biological and genetic diversity in upper tract urothelial carcinoma with patient derived xenografts. <i>Nature Communications</i> , <b>2020</b> , 11, 1975	17.4	17
38	Genomic Characterization of Upper-Tract Urothelial Carcinoma in Patients With Lynch Syndrome. <i>JCO Precision Oncology</i> , <b>2018</b> , 2018,	3.6	15
37	A delay 8 weeks to neoadjuvant chemotherapy before radical cystectomy increases the risk of upstaging. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2019</b> , 37, 116-122	2.8	13
36	Contemporary assessment of the correlation between Bosniak classification and histological characteristics of surgically removed atypical renal cysts (UroCCR-12 study). <i>World Journal of Urology</i> , <b>2018</b> , 36, 1643-1649	4	12

35	Improved decision making in intermediate-risk prostate cancer: a multicenter study on pathologic and oncologic outcomes after radical prostatectomy. <i>World Journal of Urology</i> , <b>2017</b> , 35, 1191-1197	4	10
34	Is restaging transurethral resection necessary in patients with non-muscle invasive bladder cancer and limited lamina propria invasion?. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2017</b> , 35, 603.e1-603.e5	2.8	9
33	Genomic Profile of Urothelial Carcinoma of the Upper Tract from Ureteroscopic Biopsy: Feasibility and Validation Using Matched Radical Nephroureterectomy Specimens. <i>European Urology Focus</i> , <b>2019</b> , 5, 365-368	5.1	9
32	Evidence of Atypical Recurrences After Robot-Assisted Radical Cystectomy: A Comprehensive Review of the Literature. <i>Bladder Cancer</i> , <b>2017</b> , 3, 231-236	1	8
31	Immune phenotype of peripheral blood mononuclear cells in patients with high-risk non-muscle invasive bladder cancer. <i>World Journal of Urology</i> , <b>2018</b> , 36, 1741-1748	4	8
30	Oncologic outcomes and survival in pT0 tumors after radical cystectomy in patients without neoadjuvant chemotherapy: results from a large multicentre collaborative study. <i>Annals of Surgical Oncology</i> , <b>2011</b> , 18, 3833-8	3.1	8
29	Performance Prediction for Surgical Outcomes in Partial Nephrectomy Using Nephrometry Scores: A Comparison of Arterial Based Complexity (ABC), RENAL, and PADUA Systems. <i>European Urology Oncology</i> , <b>2018</b> , 1, 428-434	6.7	8
28	Grade Group Underestimation in Prostate Biopsy: Predictive Factors and Outcomes in Candidates for Active Surveillance. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, e907-e913	3.3	7
27	External validation of a nomogram for identification of pathologically favorable disease in intermediate risk prostate cancer patients. <i>Prostate</i> , <b>2017</b> , 77, 928-933	4.2	7
26	Urology surgical activity and COVID-19: risk assessment at the epidemic peak: a Parisian multicentre experience. <i>BJU International</i> , <b>2020</b> , 126, 436-440	5.6	7
25	Pathological heterogeneity in sporadic synchronous renal tumors: Is the histological concordance predictable?. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2018</b> , 36, 11.e7-11.e12	2.8	6
24	Effectiveness of Transurethral Resection plus Systemic Chemotherapy as Definitive Treatment for Muscle Invasive Bladder Cancer in Population Level Data. <i>Journal of Urology</i> , <b>2018</b> , 200, 996-1004	2.5	6
23	The Immunoscore in Localized Urothelial Carcinoma Treated with Neoadjuvant Chemotherapy: Clinical Significance for Pathologic Responses and Overall Survival. <i>Cancers</i> , <b>2021</b> , 13,	6.6	6
22	Percutaneous Ablation Versus Robotic Partial Nephrectomy in the Treatment of cT1b Renal Tumors: Oncologic and Functional Outcomes of a Propensity Score-weighted Analysis. <i>Clinical Genitourinary Cancer</i> , <b>2020</b> , 18, 138-147	3.3	5
21	Deep Neural Networks Outperform the CAPRA Score in Predicting Biochemical Recurrence After Prostatectomy. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 607923	5.3	5
20	The impact of pathologic response to neoadjuvant chemotherapy on conditional survival among patients with muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2019</b> , 37, 572.e21-572.e28	2.8	4
19	Germ Cell Tumor Molecular Heterogeneity Revealed Through Analysis of Primary and Metastasis Pairs. <i>JCO Precision Oncology</i> , <b>2020</b> , 4,	3.6	4
18	Biopsy Core Features are Poor Predictors of Adverse Pathology in Men with Grade Group 1 Prostate Cancer. <i>Journal of Urology</i> , <b>2018</b> , 199, 961-968	2.5	4

17	Open-label phase II to evaluate the efficacy of NEOadjuvant dose-dense MVAC In cOmbination with durvalumab and tremelimumab in muscle-invasive urothelial carcinoma: NEMIO. <i>Bulletin Du Cancer</i> , <b>2020</b> , 107, eS8-eS15	2.4	4
16	PD-L1 expression and pattern of immune cells in pre-treatment specimens are associated with disease-free survival for HR-NMIBC undergoing BCG treatment. <i>World Journal of Urology</i> , <b>2021</b> , 39, 4055-4065 <sup>3</sup>		
15	Performing an early systematic Doppler-ultrasound fails to prevent hemorrhagic complications after complex partial nephrectomy. <i>Therapeutic Advances in Urology</i> , <b>2019</b> , 11, 1756287219828966	3.2	2
14	Identifying high surgical risk in muscle-invasive bladder cancer (MIBC) patients undergoing radical cystectomy (RC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 460-460	2.2	2
13	PD-L1/PD-1 expression as a predictor of response to BCG in patients with high-risk non-muscle invasive bladder cancer.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 4550-4550	2.2	2
12	TIM-3 and TIGIT are possible immune checkpoint targets in patients with bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2020</b> ,	2.8	2
11	Ejaculations and Benign Prostatic Hyperplasia: An Impossible Compromise? A Comprehensive Review.. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	2
10	Defining the DNA damage repair (DDR) genomic landscape of urothelial carcinoma of the bladder (UCB).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 502-502	2.2	1
9	Survival of Patients with Muscle-Invasive Urothelial Cancer of the Bladder with Residual Disease at Time of Cystectomy: A Comparative Survival Analysis of Treatment Modalities in the National Cancer Database. <i>Bladder Cancer</i> , <b>2020</b> , 6, 265-276	1	1
8	Impact of the COVID-19 pandemic on oncological and functional robotic-assisted surgical procedures. <i>Journal of Robotic Surgery</i> , <b>2021</b> , 15, 937-944	2.9	1
7	A kidney discard decision strategy based on zero-time histology analysis could lead to an unjustified increase in the organ turndown rate among ECD. <i>Transplant International</i> , <b>2021</b> , 34, 1506-1516		0
6	Fraley's Syndrome: A Rare Cause of Obstruction of the Collecting System. <i>Urology</i> , <b>2019</b> , 133, e7-e8	1.6	
5	The effect of tumor location on overall survival for pT2-4 bladder and upper tract urothelial carcinoma following radical surgery. <i>Canadian Urological Association Journal</i> , <b>2021</b> , 15, E248-E255	1.2	
4	The impact of neoadjuvant chemotherapy (NAC) on conditional survival (CS) among patients with muscle-invasive bladder cancer (MIBC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 520-520	2.2	
3	Effectiveness of transurethral resection (TUR) plus systemic chemotherapy as definitive treatment for muscle-invasive bladder cancer (MIBC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 481-481	2.2	
2	Administration of neoadjuvant chemotherapy for muscle-invasive bladder cancer in real life: Are urologists still too cautious?. <i>Progres En Urologie</i> , <b>2021</b> , 31, 332-339	0.9	
1	Using Contrast-Enhanced Ultrasound in Addition to Cross-Sectional Imaging for Indeterminate Renal Cysts May Lead to Overclassification in Bosniak III Category: A Case-Control Study. <i>European Surgical Research</i> , <b>2021</b> , 1-6	1.1	